Results 101 to 110 of about 5,560 (173)

Advancement of clinical practice in delivering CAR T-cell therapy: impact on healthcare resource utilization and comparison with autologous stem cell transplantation in patients with relapsed/refractory large B-cell lymphomas. [PDF]

Ann Hematol
Fehr M, Naegele M, Greiling M.
europepmc   +1 more source

A network meta-analysis of the safety of systemic treatments in patients with metastatic hormone-sensitive prostate cancer. [PDF]

Front Oncol
Di Maio M, Gonzalez-Billalabeitia E, Marandino L, Maroto P, Timsit MO, Luccarini I, Robinson P, Van Sanden S, Hadaschik BA.   +8 more
europepmc   +1 more source

Haemophilia and access to gene therapy. [PDF]

EBioMedicine
Mahlangu J.
europepmc   +1 more source

Cerebral amebiasis due to <i>Acanthamoeba</i> sp. in a patient with complete gp91 ^<i>phox</i> deficiency. [PDF]

J Hum Immun
Roelens M, Neehus AL, Rosain J, Collobert G, Boddaert N, Carausu L, Bustamante J.   +6 more
europepmc   +1 more source

Virulence and Antibiotic Resistance Genes in <i>Enterococcus</i> from Wastewater for Reuse and Their Health Impact. [PDF]

Microorganisms
Adegoke AA, Madu CE, Reddy P, Fatunla OK, Stenström TA, Okoh AI.   +5 more
europepmc   +1 more source

Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer. [PDF]

BMC Cancer
Boegemann M, Bennamoun M, Dourthe LM, Encarnacion JA, Hegele A, Hellmis E, Latorzeff I, Leicht W, Oñate-Celdrán J, Rosino-Sánchez A, Hanna K, Lencart J, Lukac M, Schioppa CA, Van Sanden S, Kramer G.   +15 more
europepmc   +1 more source

The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast. [PDF]

Oncol Ther
Halmos B, Florez N, Goldberg S, Iams W, Le X, Leal T, Nguyen D, Raez LE, Riess JW, Sabari J, Bjork D, Stigger N, Xia Y, Cifuentes P, D'Andrea D, Shanoon F, Johnson AL, Johnson ML.   +17 more
europepmc   +1 more source